A5100418817- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Immune cells in cancer
- Retinoids in leukemia and cellular processes
- Estrogen and related hormone effects
- Platelet Disorders and Treatments
- Biosimilars and Bioanalytical Methods
- Histone Deacetylase Inhibitors Research
- Immune Cell Function and Interaction
- Acute Lymphoblastic Leukemia research
- Phagocytosis and Immune Regulation
- Epigenetics and DNA Methylation
- Peptidase Inhibition and Analysis
- Blood groups and transfusion
- Cancer Immunotherapy and Biomarkers
- Drug-Induced Ocular Toxicity
- Inflammatory mediators and NSAID effects
- Eosinophilic Disorders and Syndromes
- Mechanisms of cancer metastasis
- Mesenchymal stem cell research
- Heparin-Induced Thrombocytopenia and Thrombosis
Tianjin Medical University General Hospital
2025
Air Force Medical University
2014-2024
Tang Du Hospital
2020-2024
Xi'an Medical University
2021-2024
Xi'an Jiaotong University
2022
First Affiliated Hospital of Xi'an Jiaotong University
2022
Case Western Reserve University
2022
Zhejiang University
2022
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
2022
Tianjin University of Traditional Chinese Medicine
2022
Relapse is a major cause of treatment failure after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) for high-risk acute myeloid leukemia (HR-AML). The aim this study was to explore the effect recombinant human granulocyte colony-stimulating factor (rhG-CSF) combined with minimal-dose decitabine (Dec) on prevention HR-AML relapse allo-HSCT.We conducted phase II, open-label, multicenter, randomized controlled trial. Two hundred four patients who had received allo-HSCT 60-100...
8005 Background: GC012F is a chimeric antigen receptor (CAR)-T cell therapy with B maturation (BCMA) and CD19 dual-target developed on the novel FasT CAR-T platform enabling 22-36 h manufacturing. Our previous results were presented at ASCO EHA 2022 for 29 pts (NCT04236011; NCT04182581), which demonstrated treatment led to deep durable response in RRMM pts. Furthermore, initial showed that considerable efficacy safety high-risk transplant-eligible newly diagnosed MM (Blood 2022; 140...
BackgroundTumor cells benefit from tumor-associated macrophages (TAMs) promoting tumor growth and modulating functions of other in microenvironment (TME). However, how regulate the property TAMs during invasion remains to be defined.MethodsMouse models cancer patients' samples were analyzed determine LAMP2a expression TAMs. In vitro mouse primary used assess LAMP2a-modulated macrophage activation, verify LAMP2a's target proteins. The effect LAMP2a-knockdown on progression TME maintaining was...
Abstract Background Peripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical benefit. We conducted this study to evaluate the efficacy safety of geptanolimab (GB226), an anti-PD-1 antibody, in r/r patients. Methods did single-arm, multicenter phase 2 across 41 sites China. Eligible patients with received 3 mg/kg intravenously every weeks until progression or intolerable toxicity. All who at least one dose...
Significance The APL2012 trial is currently the largest randomized, multicenter clinical study of APL based on ATRA-ATO treatment with risk stratification. We enrolled 855 newly diagnosed patients during December 2012 to 2017 for careful follow-up. All received ATRA-ATO–based protocols remission induction. At consolidation phase, key part trial, ATO was used replace or reduce chemotherapy in a risk-stratified way. Patients were then treated as maintenance. results indicated not only...
Abstract Background Hetrombopag, a novel thrombopoietin receptor agonist, has been found in phase I studies to increase platelet counts and reduce bleeding risks adults with immune thrombocytopenia (ITP). This III study aimed evaluate the efficacy safety of hetrombopag ITP patients. Methods Patients who had not responded or relapsed after previous treatment were treated an initial dosage once-daily 2.5 5 mg (defined as HETROM-2.5 HETROM-5 group) matching placebo randomized, double-blind,...
Osteoporosis is a reduction in skeletal mass because of the loss osteoblastic activity or an increase osteoclastic activity. The survival osteoblast cells plays crucial role development osteoporosis. Asperosaponin VI (ASA VI) kind saponin medicinal herb Dipsacus asper Wall which has long been used as antiosteoporosis drug. assay cell proliferation, alkaline phosphatase (ALP) and measurement mineralized matrix, showed that ASA exhibited significant induction differentiation mineralization...
The outcome of older patients with acute myeloid leukemia (AML) remains unsatisfactory. Recent studies have shown that HLA-mismatched microtransplant could improve outcomes in such patients. To evaluate different age groups among newly diagnosed AML who receive microtransplant. This multicenter clinical study included 185 de novo at 12 centers China, the United States, and Spain Microtransplantation Interest Group. Patients were divided into following 4 groups: 60 to 64 years, 65 69 70 74 75...
Abstract Background Currently, most research on hemophagocytic lymphohistiocytosis (HLH) have focused etiology and therapy, leaving few epidemiological reports. The published studies of China are mainly regional investigations. We aimed to present the overall status HLH in China, provide Chinese data for international investigation. Methods cases 2019 were collected statistically analyzed. Findings Epstein-Barr virus accounted 44.01% 1445 31 regions was common cause. Lymphoma-associated...
Abstract Chimeric antigen receptor-engineered T (CAR-T) cells have shown promising efficacy in patients with relapsed/refractory B cell acute lymphoblastic leukemia (R/R B-ALL). However, challenges remain including long manufacturing processes that need to be overcome. We presented the CD19-targeting CAR-T product GC007F manufactured next-day (FasTCAR-T cells) and administered R/R B-ALL. A total of 21 over 14 years age CD19 + B-ALL were screened, enrolled infused a single infusion at three...
Checkpoint immunotherapy is capable of unleashing T cells for controlling tumor, whereas it destroyed by immunosuppressive myeloid cell.Apoprotein E (APOE) refers to a ligand in terms the members low-density lipoprotein (LDL) receptor family mediating Apoprotein B-involving atherogenic clearance.Besides, tumor-infiltration macrophage can express APOE.The present study reported Apoe -/-mice exhibit higher resistance toward development three types carcinomas as compared with mice wild type and...
While studies have explored the feasibility of switching between various thrombopoietin receptor agonists in treating immune thrombocytopenia (ITP), data on from eltrombopag to hetrombopag remains scarce. This post-hoc analysis a phase III trial aimed assess outcomes ITP patients who switched hetrombopag. In original trial, initially randomized placebo group were eltrombopag. Those completed this 14-week eligible switch 24-week Treatment response, defined as platelet count ≥ 50 × 10